Yichang HEC Changjiang Pharmaceutical Co. Ltd.
Dongyangguang is a Chinese advanced materials conglomerate operating six divisions — electronic components, chemicals, aluminum foil, energy materials, liquid cooling, and humanoid robotics — built on vertically integrated value chains from raw materials to finished capacitors, supplying global OEMs including Panasonic, CATL, BYD, and Samsung.
- Company typePublic
- Founded1997
- HeadquartersYichang, China
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Yichang HEC Changjiang Pharmaceutical Co. Ltd. does
Dongyangguang (Guangdong Dongyangguang Science & Technology Holding Co., Ltd., 600673.SH) is a diversified advanced materials and technology conglomerate founded in 1997 and headquartered in Dongguan, China. The company operates six business divisions — electronic components, chemical new materials, high-end aluminum foil, energy materials, liquid cooling technology, and intelligent robots — supported by seven advanced manufacturing bases across Guangdong, Jiangxi, Zhejiang, Guizhou, Hubei, and Inner Mongolia, and a sales network spanning 120+ countries. Its core technology platform is built on full vertical integration spanning aluminum ingots → electronic light foil → electrode foil → capacitors, plus a chlorofluorocarbon value chain running from rock salt mining through chlor-alkali to refrigerants and PVDF. The company holds the world's exclusive patent for laminated foil (CN102017034B, CN102009170B) and is the only global producer of laminated foil and multilayer foil capacitors, technologies critical to AI server power supplies.
The company generates revenue primarily through B2B direct sales of hardware materials to global enterprise OEMs, including Panasonic, CATL, BYD, Gree, Midea, Haier, Samsung, and — increasingly — TDK, NipponChemi-Con, and YAGEO for AI server capacitor foils. The pharmaceutical arm (东阳光药, 06887.HK) operates a separate distribution model targeting oncology, including a NewCo with US AI drug design firm Accutar for RIPTAC pipeline commercialization (mCRPC first indication). Newer revenue streams include humanoid robotics via the 光谷东智 JV with Zhiyuan Robot, and liquid cooling systems (immersion, cold plate, CDU) targeting data centers and AI supercomputing facilities. Recent commercial positioning emphasizes an integrated 'power components / chemical new materials — liquid cooling — computing operations — AI applications' industry chain, with AI applied both internally (AI Research Institute, AI visual inspection) and through strategic partnerships (Accutar for drug discovery, Zhiyuan for embodied AI).
Yichang HEC Changjiang Pharmaceutical Co. Ltd. firmographics
Firmographics- Name
- Yichang HEC Changjiang Pharmaceutical Co. Ltd.
- Legal name
- Guangdong Dongyangguang Science & Technology Holding Co., Ltd. (广东东阳光科技控股股份有限公司)
- Website
- https://hec-al.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Dongyangguang is a Chinese advanced materials conglomerate operating six divisions — electronic components, chemicals, aluminum foil, energy materials, liquid cooling, and humanoid robotics — built on vertically integrated value chains from raw materials to finished capacitors, supplying global OEMs including Panasonic, CATL, BYD, and Samsung.
- Ownership category
- akta.pro rank
Yichang HEC Changjiang Pharmaceutical Co. Ltd. industry classification
Industry- Product category
- Oncology Pharmaceutical R&D
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
Keywords
Where Yichang HEC Changjiang Pharmaceutical Co. Ltd. is headquartered
LocationHeadquarters
- HQ city
- Yichang
- HQ country
- China
- HQ region
- Asia
Offices12 records
Markets served
Yichang HEC Changjiang Pharmaceutical Co. Ltd. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Electronic Components (Capacitors & Foils): Sales of electronic light foil, electrode foil, laminated foil, aluminum electrolytic capacitors, supercapacitors, and multilayer foil capacitors. Complete 'aluminum ingots - electronic light foil - electrode foil - capacitors' value chain. Revenue generated from global enterprise customers in consumer electronics, new energy vehicles, photovoltaic energy storage, and AI server markets.
- Chemical New Materials: Sales of chlorofluorocarbon chain products including refrigerants (R32, R125, R134a), PVDF, methane chlorides, hydrogen peroxide, caustic soda, hydrochloric acid, liquid chlorine, and wet electronic chemicals. Customers include Gree, Midea, Haier, Shanghai Daikin, Samsung.
- High-end Aluminum Foil: Sales of battery aluminum foil, carbon-coated aluminum foil, brazing foil, hydrophilic foil, double-zero foil, lunch box foil, and flat-rolled products. Supplies Panasonic, CATL, BYD, and other leading global enterprises.
- Energy Materials: Sales of cathode materials (lithium iron phosphate, ternary materials), magnetic materials (ferrite, Fe-Si-Cr alloy), and coal from owned mining operations. Also includes lithium ore resource development with strategic partner GAC Group.
- Liquid Cooling Technology Solutions: Sales of immersion liquid-cooled all-in-one machines, liquid cooling heat dissipation systems, CDU units, cold plates, manifolds, and fluid connectors. Provides integrated liquid cooling solutions for data centers, 5G base stations, and AI supercomputing centers.
- Intelligent Robots: Sales of humanoid robots (光子和/Photon) and AI-powered service robots. Includes robotics for industrial inspection, healthcare, elderly care, and general service applications. 光谷东智 subsidiary targets annual capacity of 1,000+ units.
- Pharmaceutical R&D and Licensing (东阳光药): Drug development through NewCo structure with partners for RIPTAC pipeline targeting mCRPC. 东阳光药 (stock code 06887.HK) maintains pharmaceutical commercial operations in China with international registration capabilities (FDA, NMPA).
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. product offering
Product offeringCore offering
Yichang HEC Changjiang Pharmaceutical Co. Ltd. (东阳光药, stock code 06887.HK) is the pharmaceutical subsidiary of the Dongyangguang Group, focused on the development of innovative oncology drugs. Its core pipeline is built on RIPTAC (Regulated Induced Proximity Target Androgen Receptor Chimeras) technology, a novel bifunctional small-molecule therapeutic platform co-incubated with US-based Accutar Bio-Pharmaceutical through a NewCo structure for the treatment of metastatic castration-resistant prostate cancer (mCRPC), with potential expansion into multiple solid tumor indications.
Differentiator
Problem solved
Functional benefit
Brands
- 光谷东智 (Guanggu Dongzhi): Joint venture brand for embodied intelligence and humanoid robots, launched in Wuhan Optical Valley in 2025, producing humanoid robot 'Photon'
- 光子 (Photon)
Products and services
- RIPTAC Oncology Pipeline (mCRPC Lead Indication) A proprietary RIPTAC-based small-molecule drug development pipeline targeting metastatic castration-resistant prostate cancer (mCRPC), developed jointly through a NewCo structure with Accutar Bio-Pharmaceutical. RIPTAC molecules use a bifunctional mechanism where one end binds a tumor-specific target protein and the other end binds an essential cell-survival protein, achieving selective tumor cell killing while naturally avoiding E3 ligase mutation-related resistance. Validated by Johnson & Johnson's USD 3.05 billion acquisition of Halda Therapeutics in November 2025. Initial candidate (Halda-derived) showed PSA50 response of 59% and PSA90 of 32% in Phase I mCRPC trial.
Quantifiable outcome
- 40%+ capacity increase with laminated foil at same voltage
- +8 more outcomes
Companies that use Yichang HEC Changjiang Pharmaceutical Co. Ltd.
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles2 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- TDK CorporationcoreOn July 16, 2026, Dongyangguang and TDK signed a cooperation Memorandum of Understanding (MOU) to deepen cooperation in laminated formed foil and laminated foil capacitor fields. Both parties leverage各自 advantages in key materials, product R&D, manufacturing capabilities, and market resources. The partnership aims to jointly explore new paths for electronic components industry collaborative development, better serving high-end applications such as AI servers.
- NipponChemi-Con (贵弥功/NCC)coreOn July 14, 2026, NipponChemi-Con社长今野健一 led a delegation to visit Dongyangguang's Ulanqab base. NCC is the world's largest aluminum electrolytic capacitor manufacturer by market share. Discussions focused on securing laminated foil supply for 2027 and beyond, as well as technical development roadmaps for laminated foil capacitors. NCC recognized Dongyangguang's capacity layout and large-scale manufacturing capabilities.
- YAGEO Group (国巨)coreOn July 13, 2026, YAGEO Group's aluminum electrolytic capacitor division VP and TFE business group supply chain VP led a team from Europe to visit Dongyangguang's Ulanqab base. As a global passive component giant, YAGEO sought to secure laminated foil supply for 2027 AI server applications. Both parties conducted in-depth discussions on laminated foil capacitor technology development roadmaps and product R&D application directions.
- Accutar Bio-Pharmaceutical (美国AI制药企业)coreOn June 24, 2026, 东阳光药 (Dongyangguang Pharmaceutical, stock 06887.HK) and Accutar signed an agreement to establish a NewCo company to co-incubate RIPTAC (Regulated Induced Proximity Target Androgen Receptor Chimeras) technology innovation drug pipelines. First indication is metastatic castration-resistant prostate cancer (mCRPC). Dongyangguang Pharmaceutical holds controlling interest in NewCo and retains all global development rights,主导后期 development and commercialization. Accutar contributes AI drug design platform and RIPTAC technology.
- Zhiyuan Robot (智元机器人/Shanghai Zhiyuan New Innovation Technology Co., Ltd.)coreOn March 29, 2025, Dongyangguang, 光谷东智 and Zhiyuan Robot signed strategic cooperation agreements with Wuhan East Lake New Technology Development Zone Management Committee, Wuhan Optics Valley Central City Construction Service Center, and Hubei Science and Technology Investment Group.三方 to jointly build China's largest and most advanced humanoid robot innovation center in East Lake High-tech Zone. 光谷东智 (jointly established by Dongyangguang, Zhiyuan Robot, Beiwu Academy, and Lingchu Intelligence in February 2025) will build humanoid robot production lines and release full-range robot products and embodied intelligence models.
- Wuhan East Lake New Technology Development Zone Management Committee (武汉东湖新技术开发区管理委员会)coreThree-party strategic cooperation framework agreement signed to build China's largest humanoid robot innovation center in Optics Valley. The committee will support 光谷东智 in building the national headquarters project and promote high-quality development of Optics Valley AI industry.
- Beiwu Academy (北武院)minorCo-founding partner of 光谷东智 alongside Dongyangguang, Zhiyuan Robot, and Lingchu Intelligence. Will assist in releasing 'embodied intelligence general basic model' at the Optics Valley innovation center launch.
- Lingchu Intelligence (灵初智能)minorCo-founding partner of 光谷东智 alongside Dongyangguang, Zhiyuan Robot, and Beiwu Academy. Founder Wang Qibin attended the March 29 signing ceremony.
- Toyo Aluminium (日本东洋铝)coreJoint development of powder laminated foil technology with Japan's Toyo Aluminium. This global-first technology led to Dongyangguang obtaining the world's exclusive laminated foil patent. The partnership has been the foundation for Dongyangguang's leadership in this technology area.
- Guangdong New Energy Storage National Research Institute Co., Ltd. (广东省新储能产业创新研究院有限公司)minorJoint laboratory established with Guangdong New Energy Storage National Research Institute at the Guangzhou Research Institute. Conducts frontier technology R&D in energy storage materials including lithium-ion, sodium-ion, and solid-state batteries.
- Japan UACJminorDeep R&D cooperation with Japan UACJ for new energy storage and advanced aluminum foil technologies. Part of Dongyangguang's international technology collaboration network.
- China Southern Power Grid (南方电网)minorIn-depth cooperation with China Southern Power Grid on energy storage technology development. Dongyangguang participated in establishing a national-level new energy storage innovation center.
- China Electronics Technology Group (中国电子科技集团)minorImplied strategic channel partner for supplying electronic materials and components into China's defense and electronics technology supply chains.
- GAC Group (广汽集团)minorStrategic cooperation with GAC Group and Zunyi Municipal Government to jointly develop lithium ore resources in Guizhou Province. Supports upstream raw material supply for EV battery value chain.
Scale indicators34 records
Recent moves6 records
Expansion highlights6 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. competitors and assessment
Company assessmentDirect peers
- NipponChemi-Con: The world's largest aluminum electrolytic capacitor manufacturer by market share and a strategic customer of Dongyangguang for laminated foil supply into AI server capacitors. Direct counterparty in the capacitor value chain; its 2027 supply roadmap directly determines Dongyangguang's laminated foil revenue trajectory.
- Nichicon: Major Japanese aluminum electrolytic capacitor manufacturer competing in the same end markets (consumer electronics, automotive, industrial, AI server). Highly comparable as a vertically integrated capacitor producer with similar customer overlap to Dongyangguang's electrode foil and capacitor segments.
- Wuxi Shuangrong New Material Technology (无锡双瑞): Chinese electrode foil and aluminum capacitor materials manufacturer directly competing with Dongyangguang in the mid- and high-voltage formed foil market. Operates similar capacitor material production lines and serves overlapping Chinese consumer electronics and industrial customers.
- Easpring Material Technology (当升科技): Chinese cathode materials manufacturer producing LFP and ternary cathode materials for lithium-ion batteries. Directly comparable to Dongyangguang's energy materials segment, with overlapping end customers in EV and energy storage battery supply chains.
- Jiangsu Dingsheng New Energy Materials (鼎胜新材): Chinese battery aluminum foil manufacturer with leading global market share in lithium battery foil. Directly comparable to Dongyangguang's high-end aluminum foil division (battery aluminum foil, carbon-coated aluminum foil), competing for the same EV battery supply chain customers.
- Zhejiang Juhua (巨化股份): Major Chinese fluorochemical company producing refrigerants, PVDF, and fluoropolymers. Directly comparable to Dongyangguang's chemical new materials division (R32/R125/R134a refrigerants, PVDF, methane chlorides), competing for HVAC and lithium battery binder customers.
Broad incumbents
- TDK Corporation: Global electronic components giant that signed a July 2026 MOU with Dongyangguang for laminated formed foil and laminated foil capacitor collaboration. Operates broadly across capacitors, inductors, sensors, and batteries; AI server capacitor demand is a key overlap with Dongyangguang's growth thesis.
- YAGEO Corporation: Global passive component giant that visited Dongyangguang's Ulanqab base in July 2026 to secure laminated foil supply for 2027 AI server applications. Comparable as a broad-line passive component incumbent whose capacitor business depends on Dongyangguang's laminated foil inputs.
- Murata Manufacturing: World's largest MLCC manufacturer with broad passive component portfolio spanning capacitors, inductors, and EMI filters. Comparable as a large Japanese electronic components incumbent whose capacitor roadmap intersects Dongyangguang's electrode foil and capacitor materials business.
- Vertiv Holdings: Global data center thermal management and power infrastructure leader offering immersion cooling, CDU, and precision cooling solutions. Comparable to Dongyangguang's liquid cooling technology segment as both target AI data center and hyperscaler cooling demand.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Yichang HEC Changjiang Pharmaceutical Co. Ltd. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yichang HEC Changjiang Pharmaceutical Co. Ltd. leadership team
Management profileNumber of profiles
Profiles3 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. subsidiaries and ownership
Company hierarchySubsidiaries3 records
Yichang HEC Changjiang Pharmaceutical Co. Ltd. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yichang HEC Changjiang Pharmaceutical Co. Ltd. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yichang HEC Changjiang Pharmaceutical Co. Ltd.
What does Yichang HEC Changjiang Pharmaceutical Co. Ltd. do?
Yichang HEC Changjiang Pharmaceutical Co. Ltd. (东阳光药, stock code 06887.HK) is the pharmaceutical subsidiary of the Dongyangguang Group, focused on the development of innovative oncology drugs. Its core pipeline is built on RIPTAC (Regulated Induced Proximity Target Androgen Receptor Chimeras) technology, a novel bifunctional small-molecule therapeutic platform co-incubated with US-based Accutar Bio-Pharmaceutical through a NewCo structure for the treatment of metastatic castration-resistant prostate cancer (mCRPC), with potential expansion into multiple solid tumor indications.
Is Yichang HEC Changjiang Pharmaceutical Co. Ltd. a public or private company?
Yichang HEC Changjiang Pharmaceutical Co. Ltd. is a public company. It is classified as public and is currently operating.
When was Yichang HEC Changjiang Pharmaceutical Co. Ltd. founded?
Yichang HEC Changjiang Pharmaceutical Co. Ltd. was founded in 1997. It employs 101 to 250 people.
Where is Yichang HEC Changjiang Pharmaceutical Co. Ltd. based?
Yichang HEC Changjiang Pharmaceutical Co. Ltd. is headquartered in Yichang, China, in the Asia region.
How does Yichang HEC Changjiang Pharmaceutical Co. Ltd. make money?
Seven revenue lines are on record. Electronic Components (Capacitors & Foils) is the primary driver. The others are chemical New Materials, high-end Aluminum Foil, energy Materials, liquid Cooling Technology Solutions, intelligent Robots and pharmaceutical R&D and Licensing (东阳光药).
Who are Yichang HEC Changjiang Pharmaceutical Co. Ltd.'s main competitors?
Direct peers on record are NipponChemi-Con, Nichicon, Wuxi Shuangrong New Material Technology (无锡双瑞), Easpring Material Technology (当升科技), Jiangsu Dingsheng New Energy Materials (鼎胜新材) and Zhejiang Juhua (巨化股份). Broad incumbents are TDK Corporation, YAGEO Corporation, Murata Manufacturing and Vertiv Holdings.
Does Yichang HEC Changjiang Pharmaceutical Co. Ltd. have an API?
No public API is recorded for Yichang HEC Changjiang Pharmaceutical Co. Ltd..
What industry is Yichang HEC Changjiang Pharmaceutical Co. Ltd. in?
Yichang HEC Changjiang Pharmaceutical Co. Ltd.'s product category is Oncology Pharmaceutical R&D. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325412 and its SIC code is 2834.